Evidence map›Paper›PMID 35199072›Full record

ReviewCurrent research in microbial sciences2022

Riboflavin as a promising antimicrobial agent? A multi-perspective review.

Nuratiqah Farah, Voon Kin Chin, Pei Pei Chong, Wai Feng Lim, Chee Woei Lim, Rusliza Basir, Sui Kiat Chang, Tze Yan Lee

Open access · goldAbstract readReview
In one paragraph

Review in Current research in microbial sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
12.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 88 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Membrane-Targeting Antivirals.International journal of molecular sciences · 2025
    Review
  11. Article
  12. Article
  13. Successful photodynamic therapy for infectious complications of abdominoplasty using mesh implants: a case report.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2025
    Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Inhibition of Monkeypox Virus DNA Polymerase UsingIndian journal of microbiology · 2024
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Nuratiqah FarahDepartment of Human Anatomy, Faculty of Medicine and Health Sciences, UPM, 43400, Serdang, Selangor, Malaysia.
Voon Kin ChinDepartment of Medical Microbiology, Faculty of Medicine and Health Sciences, UPM, 43400, Serdang, Selangor, Malaysia.
Pei Pei ChongSchool of Biosciences, Taylor's University, No 1, Jalan Taylor's, 47500 Subang Jaya, Selangor, Malaysia.
Wai Feng LimIntegrative Pharmacogenomics Institute (iPROMISE), Universiti Teknologi MARA, Puncak Alam Campus, 42300 Bandar Puncak Alam, Selangor, Malaysia.
Chee Woei LimDepartment of Medicine, Faculty of Medicine and Health Sciences, UPM, 43400, Serdang, Selangor, Malaysia.
Rusliza BasirDepartment of Human Anatomy, Faculty of Medicine and Health Sciences, UPM, 43400, Serdang, Selangor, Malaysia.
Sui Kiat ChangDepartment of Horticulture, Key Laboratory of South China Agricultural Plant Molecular Analysis and Genetic Improvement, Key Laboratory of Post-Harvest Handling of Fruits, Ministry of Agriculture. South China Botanical Garden, Chinese Academy of Sciences. Guangzhou, 510650 China.
Tze Yan LeePerdana University School of Liberal Arts, Science and Technology (PUScLST), Suite 9.2, 9th Floor, Wisma Chase Perdana, Changkat Semantan, Damansara Heights, 50490 Kuala Lumpur, Malaysia.
Serdang Hospital · MYPerdana University · MYSouth China Botanical Garden · CNTaylor's University · MYUniversiti Teknologi MARA · MY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Riboflavin, or more commonly known as vitamin B2, forms part of the component of vitamin B complex. Riboflavin consisting of two important cofactors, flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD), which are involved in multiple oxidative-reduction processes and energy metabolism. Besides maintaining human health, different sources reported that riboflavin can inhibit or inactivate the growth of different pathogens including bacteria, viruses, fungi and parasites, highlighting the possible role of riboflavin as an antimicrobial agent. Moreover, riboflavin and flavins could produce reactive oxygen species (ROS) when exposed to light, inducing oxidative damage in cells and tissues, and thus are excellent natural photosensitizers. Several studies have illustrated the therapeutic efficacy of photoactivated riboflavin against nosocomial infections and multidrug resistant bacterial infections as well as microbial associated biofilm infections, revealing the potential role of riboflavin as a promising antimicrobial candidate, which could serve as one of the alternatives in fighting the global crisis of the emergence of antimicrobial resistance seen in different pathogenic microbes. Riboflavin could also be involved in modulating host immune responses, which might increase the pathogen clearance from host cells and increase host defense against microbial infections. Thus, the dual effects of riboflavin on both pathogens and host immunity, reflected by its potent bactericidal effect and alleviation of inflammation in host cells further imply that riboflavin could be a potential candidate for therapeutic intervention in resolving microbial infections. Hence, this review aimed to provide some insights on the promising role of riboflavin as an antimicrobial candidate and also a host immune-modulator from a multi-perspective view as well as to discuss the application and challenges on using riboflavin in photodynamic therapy against various pathogens and microbial biofilm-associated infections.

Indexed as

AntibiofilmAntimicrobialImmune-modulationPhotosensitiserRiboflavin

Identifiers

PMID35199072
PMCPMC8848291
OpenAlexW4211040556

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.